PROCEEDINGS OF SPIE

Biosensing and Nanomedicine IV

Hooman Mohseni
Massoud H. Agahi
Manijeh Razeghi
Editors

21–23 August 2011
San Diego, California, United States

Sponsored and Published by
SPIE

Volume 8099

Proceedings of SPIE, 0277-786X, v. 8099

The papers included in this volume were part of the technical conference cited on the cover and title page. Papers were selected and subject to review by the editors and conference program committee. Some conference presentations may not be available for publication. The papers published in these proceedings reflect the work and thoughts of the authors and are published herein as submitted. The publisher is not responsible for the validity of the information or for any outcomes resulting from reliance thereon.

Please use the following format to cite material from this book:
Author(s), "Title of Paper," in *Biosensing and Nanomedicine IV*, edited by Hooman Mohseni, Massoud H. Agahi, Manijeh Razeghi, Proceedings of SPIE Vol. 8099 (SPIE, Bellingham, WA, 2011) Article CID Number.

ISSN 0277-786X
ISBN 9780819487094

Published by
SPIE
P.O. Box 10, Bellingham, Washington 98227-0010 USA
Telephone +1 360 676 3290 (Pacific Time) · Fax +1 360 647 1445
SPIE.org

Printed in the United States of America.

Publication of record for individual papers is online in the SPIE Digital Library.

SPIEDigitalLibrary.org

Paper Numbering: Proceedings of SPIE follow an e-First publication model, with papers published first online and then in print and on CD-ROM. Papers are published as they are submitted and meet publication criteria. A unique, consistent, permanent citation identifier (CID) number is assigned to each article at the time of the first publication. Utilization of CIDs allows articles to be fully citable as soon as they are published online, and connects the same identifier to all online, print, and electronic versions of the publication. SPIE uses a six-digit CID article numbering system in which:

- The first four digits correspond to the SPIE volume number.
- The last two digits indicate publication order within the volume using a Base 36 numbering system employing both numerals and letters. These two-number sets start with 00, 01, 02, 03, 04, 05, 06, 07, 08, 09, 0A, 0B … 0Z, followed by 10-1Z, 20-2Z, etc.

The CID number appears on each page of the manuscript. The complete citation is used on the first page, and an abbreviated version on subsequent pages. Numbers in the index correspond to the last two digits of the six-digit CID number.

Contents

POSTER SESSION

Conference Committee

Symposium Chairs

David L. Andrews, University of East Anglia Norwich (United Kingdom)
James G. Grote, Air Force Research Laboratory (United States)

Conference Chairs

Hooman Mohseni, Northwestern University (United States)
Massoud H. Agahi, Harbor-UCLA Medical Center (United States) and Cedars-Sinai Medical Center (United States)
Manijeh Razeghi, Northwestern University (United States)

Program Committee

Gert Cauwenberghs, University of California, San Diego (United States)
Philippe M. Fauchet, University of Rochester (United States)
David H. Gracias, The Johns Hopkins University (United States)
Kimberly S. Hamad-Schifferli, Massachusetts Institute of Technology (United States)
James Sean Humbert, University of Maryland, College Park (United States)
Giacomo Indiveri, ETH Zürich (Switzerland)
Eric Lagally, The University of British Columbia (Canada)
Yu-Hwa Lo, University of California, San Diego (United States)
Ryan P. McClintock, Northwestern University (United States)
Omer G. Memis, Northwestern University (United States)
Masoud Panjehpour, Thompson Cancer Survival Center (United States)
Adam T. Woolley, Brigham Young University (United States)
John M. Zavada, National Science Foundation (United States)

Session Chairs

New Horizons in Imaging
Massoud H. Agahi, Harbor-UCLA Medical Center (United States)
Hooman Mohseni, Northwestern University (United States)

Targeted Delivery of Diagnostic and Therapeutic Agents
Massoud H. Agahi, Harbor-UCLA Medical Center (United States)
Hooman Mohseni, Northwestern University (United States)

Biosensing and Tele-health
Massoud H. Agahi, Harbor-UCLA Medical Center (United States)
Hooman Mohseni, Northwestern University (United States)

Biosensors for Diagnostic and Theranostics
Mikella E. Hankus, U.S. Army Research Laboratory (United States)
Andrea M. Armani, The University of Southern California (United States)

Biomolecule Detection and Sensing
Hatice Altug, Boston University (United States)

Biosensing I
Trisha V. Eustaquio, Purdue University (United States)
Patrick Chin, TNO (Netherlands)

Biosensing II
Omer Golkap Memis, Northwestern University (United States)

Introduction

Since its debut in 2008, the "Biosensing" conference track quite naturally provided a forum for not only the latest research in this rapidly developing field of nanoscience, but also an opportunity for the biomedical- and engineer-researchers to interface directly. The potential was recognized by the conference organizers that by serving as a bridge between these dynamic scientific communities, it can be a catalyst for fruitful collaborations.

It was toward optimizing this potential for promoting innovative solutions to important healthcare problems that the 2011 conference marks the implementation of some related measures. A number of invited lectures were included in the program that were selected for the clinical relevance of the technology and their significant potential impact in the healthcare community. Indeed, the first day's program was tightly packed with lectures and speakers that would appeal to a mixed audience of engineers, physicians, and other interested scientists and clinicians. Our aim is to address a wide range of topics and issues of interest to the biomedical applications of nanotechnology, such as imaging, drug delivery, diagnostics, toxicity, ethics, economics, and regulatory matters.

To further emphasize this aspect of the mission of the conference to promote a forum for collaboration among the scientific, technical, clinical, and industrial communities, the official title was changed to "Biosensing & Nanomedicine", a physician co-chair was added, and the conference was evaluated and approved as a provider of Continuing Medical Education (CME) credits. To qualify for the latter, the first day's program was planned and implemented in accordance with the Institute for Medical Quality and the California Medical Association's CME Accreditation Standards (IMQ/CMA). Thus we are proud to be able to offer up to 9 hours of AMA PRA Category 1 Credits to our qualifying attendees.

Despite these measures to enhance the clinical relevance of "Biosensing", it remains dedicated to its core mission of bringing the highest level of quality research and development in nanoscience and engineering to the world stage. The "Diagnostic and Theronostics", "Biomolecule Detection," and the general "Biosensing" sessions were again held with a number of dynamic topics and discussions which will surely continue to be areas of intense research in the coming years.

We are excited about the potential contributions of these investigators to their respective fields and will continue to bring their important work to the attention of our conference attendees and readership of the Proceedings.

Hooman Mohseni
Manijeh Razeghi
Massoud Agahi